Filter articles using the following links

Videocast of the Annual General Meeting held on May 13, 2025 in Paris, France

GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025

GenSight Biologics Annual General Meeting on May 13, 2025

GenSight Biologics Announces the Filing of its 2024 Universal Registration Document

GenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business Update

GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates

GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2025

GenSight Biologics announces financing amounting to c. €0.9 million from existing investors

GenSight Biologics Reports Estimated Full-Year 2024 Consolidated Financial Results

GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study